89bio (ETNB) Competitors $9.14 +1.36 (+17.48%) (As of 11/1/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends ETNB vs. ICPT, ALBO, ARWR, PTCT, EWTX, IOVA, ZLAB, RYTM, MLTX, and BHCShould you be buying 89bio stock or one of its competitors? The main competitors of 89bio include Intercept Pharmaceuticals (ICPT), Albireo Pharma (ALBO), Arrowhead Pharmaceuticals (ARWR), PTC Therapeutics (PTCT), Edgewise Therapeutics (EWTX), Iovance Biotherapeutics (IOVA), Zai Lab (ZLAB), Rhythm Pharmaceuticals (RYTM), MoonLake Immunotherapeutics (MLTX), and Bausch Health Companies (BHC). These companies are all part of the "medical" sector. 89bio vs. Intercept Pharmaceuticals Albireo Pharma Arrowhead Pharmaceuticals PTC Therapeutics Edgewise Therapeutics Iovance Biotherapeutics Zai Lab Rhythm Pharmaceuticals MoonLake Immunotherapeutics Bausch Health Companies 89bio (NASDAQ:ETNB) and Intercept Pharmaceuticals (NASDAQ:ICPT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation, dividends, media sentiment and community ranking. Does the media favor ETNB or ICPT? In the previous week, 89bio had 3 more articles in the media than Intercept Pharmaceuticals. MarketBeat recorded 3 mentions for 89bio and 0 mentions for Intercept Pharmaceuticals. 89bio's average media sentiment score of 0.51 beat Intercept Pharmaceuticals' score of 0.30 indicating that 89bio is being referred to more favorably in the media. Company Overall Sentiment 89bio Positive Intercept Pharmaceuticals Neutral Which has better valuation and earnings, ETNB or ICPT? Intercept Pharmaceuticals has higher revenue and earnings than 89bio. Intercept Pharmaceuticals is trading at a lower price-to-earnings ratio than 89bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio89bioN/AN/A-$142.19M-$1.97-4.64Intercept Pharmaceuticals$285.71M2.78$221.82M-$1.48-12.84 Which has more volatility and risk, ETNB or ICPT? 89bio has a beta of 1.09, indicating that its stock price is 9% more volatile than the S&P 500. Comparatively, Intercept Pharmaceuticals has a beta of 0.88, indicating that its stock price is 12% less volatile than the S&P 500. Do institutionals and insiders hold more shares of ETNB or ICPT? 83.8% of Intercept Pharmaceuticals shares are owned by institutional investors. 2.8% of 89bio shares are owned by company insiders. Comparatively, 6.2% of Intercept Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the MarketBeat Community prefer ETNB or ICPT? Intercept Pharmaceuticals received 961 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 71.35% of users gave Intercept Pharmaceuticals an outperform vote while only 64.02% of users gave 89bio an outperform vote. CompanyUnderperformOutperform89bioOutperform Votes10564.02% Underperform Votes5935.98% Intercept PharmaceuticalsOutperform Votes106671.35% Underperform Votes42828.65% Is ETNB or ICPT more profitable? 89bio has a net margin of 0.00% compared to Intercept Pharmaceuticals' net margin of -19.39%. 89bio's return on equity of -35.42% beat Intercept Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets 89bioN/A -35.42% -31.52% Intercept Pharmaceuticals -19.39%-77.48%-11.99% Do analysts prefer ETNB or ICPT? 89bio currently has a consensus price target of $31.00, suggesting a potential upside of 239.17%. Given 89bio's higher probable upside, research analysts clearly believe 89bio is more favorable than Intercept Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score 89bio 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.86Intercept Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/A Summary89bio beats Intercept Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get 89bio News Delivered to You Automatically Sign up to receive the latest news and ratings for ETNB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETNB vs. The Competition Export to ExcelMetric89bioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$899.19M$7.41B$5.48B$8.52BDividend YieldN/A7.92%5.07%4.13%P/E Ratio-4.6412.34128.5016.14Price / SalesN/A400.631,495.8497.42Price / CashN/A47.4339.6734.18Price / Book1.595.604.765.07Net Income-$142.19M$153.56M$119.00M$225.46M7 Day Performance16.14%0.13%0.79%0.54%1 Month Performance25.90%15.20%5.64%3.75%1 Year Performance15.11%41.11%36.71%29.48% 89bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETNB89bio1.731 of 5 stars$9.14+17.5%$31.00+239.2%+15.5%$899.19MN/A-4.6440News CoverageHigh Trading VolumeICPTIntercept PharmaceuticalsN/A$19.00flatN/AN/A$794.77M$285.71M-12.84341Analyst ForecastALBOAlbireo PharmaN/A$44.15-0.2%N/A+0.0%$913.91M$40.58M-6.57130ARWRArrowhead Pharmaceuticals4.2483 of 5 stars$19.71-1.4%$45.33+130.0%-24.4%$2.45B$19.65M-4.22400News CoveragePTCTPTC Therapeutics2.9842 of 5 stars$40.66-4.3%$40.08-1.4%+119.3%$3.13B$937.82M-6.441,410Upcoming EarningsEWTXEdgewise Therapeutics2.0142 of 5 stars$33.32-3.3%$35.60+6.8%+427.1%$3.12BN/A-21.5060Short Interest ↓Positive NewsIOVAIovance Biotherapeutics3.7609 of 5 stars$11.04+2.1%$22.33+102.3%+189.1%$3.09B$32.77M-6.61500Upcoming EarningsZLABZai Lab3.0579 of 5 stars$30.84-1.9%$52.50+70.2%+23.1%$3.07B$322.71M-10.082,175Gap DownRYTMRhythm Pharmaceuticals3.3956 of 5 stars$49.54flat$60.33+21.8%+104.3%$3.02B$101.78M-11.36140Upcoming EarningsAnalyst ForecastMLTXMoonLake Immunotherapeutics1.6766 of 5 stars$47.00-2.5%$80.45+71.2%-3.7%$3.00BN/A-51.652News CoveragePositive NewsBHCBausch Health Companies3.925 of 5 stars$8.18+0.2%$7.33-10.4%+38.1%$2.95B$9.20B-6.3920,270Earnings ReportAnalyst ForecastOptions VolumeNews Coverage Related Companies and Tools Related Companies Intercept Pharmaceuticals Alternatives Albireo Pharma Alternatives Arrowhead Pharmaceuticals Alternatives PTC Therapeutics Alternatives Edgewise Therapeutics Alternatives Iovance Biotherapeutics Alternatives Zai Lab Alternatives Rhythm Pharmaceuticals Alternatives MoonLake Immunotherapeutics Alternatives Bausch Health Companies Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ETNB) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | SponsoredHow Will You Survive A Post Election Retirement Heist?The clock is ticking, and your life savings are in an extremely vulnerable position. We are a few days away...American Hartford Gold Group | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Final FrontierAnd a lot of powerful investors would rather this exposé never saw the light of day. I suspect they’ll attempt...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 89bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 89bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
